GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)
/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food...
Yu Wang Nova Science Pub Inc University Of Colorado Anschutz Medical Campus Drug Administration China Hypertension Genfleet Therapeutics
Source: prnewswire.com